Boston Scientific price target lowered to $90 from $92 at Truist

Truist lowered the firm’s price target on Boston Scientific (BSX) to $90 from $92 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in MedTech. The firm expects Q1 performances to be in line or better than what feels like an anxious investor sentiment around Q1 volumes, the analyst tells investors in a research note. Reduced price target reflects some multiple contraction for the group since the firm’s last valuation update, though the firm also believes that the stock’s valuation can at a minimum rebound back up to its one-year forward earnings of 23-times, Truist added.